Trial Profile
An eight- week randomized, double-blind, placebo-controlled, parallel group proof of concept study to assess the efficacy, safety and tolerability as well as the pharmacokinetic profile of oral solabegron (GW427353) 125mg and 50mg administered twice daily vs placebo in women with overactive bladder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Sep 2023
Price :
$35
*
At a glance
- Drugs Solabegron (Primary)
- Indications Overactive bladder
- Focus Proof of concept; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 28 Feb 2012 Results presented at the 27th Congress of the European Association of Urology.
- 25 Mar 2011 Positive top-line results reported in a AltheRx media release.
- 18 Jan 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.